Agenus shared a post on LinkedIn:
“Immunotherapy has reshaped expectations in oncology, but its impact remains uneven across tumor types and patient populations.
For cancers that remain resistant to current approaches, the next chapter of progress will require strategies designed to activate and sustain immune response in harder-to-treat disease.
At Agenus, we are focused on advancing that work.”
More posts about Agenus